Passage Bio, Inc.
PASG
$7.37
-$0.27-3.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.46% | -40.04% | -30.57% | -6.60% | -25.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.54% | -45.59% | -39.00% | -23.42% | -22.64% |
| Operating Income | 27.54% | 45.59% | 39.00% | 23.42% | 22.64% |
| Income Before Tax | -2.03% | 59.93% | 41.31% | 7.82% | 24.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.03% | 59.93% | 41.31% | 7.82% | 24.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.03% | 59.93% | 41.31% | 7.82% | 24.07% |
| EBIT | 27.54% | 45.59% | 39.00% | 23.42% | 22.64% |
| EBITDA | 25.00% | 44.06% | 37.03% | 21.01% | 23.18% |
| EPS Basic | -1.11% | 60.34% | 41.80% | 16.44% | 33.88% |
| Normalized Basic EPS | 26.20% | 47.26% | 40.16% | 30.75% | 33.88% |
| EPS Diluted | -1.11% | 60.34% | 41.80% | 16.44% | 33.88% |
| Normalized Diluted EPS | 26.20% | 47.26% | 40.16% | 30.75% | 33.88% |
| Average Basic Shares Outstanding | 0.90% | 1.02% | 0.84% | 10.33% | 14.84% |
| Average Diluted Shares Outstanding | 0.90% | 1.02% | 0.84% | 10.33% | 14.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |